DIANA HAUSMAN
CIK 1563992 · Chief Medical Officer · last filed 2026-06-11
DIANA HAUSMAN is a Chief Medical Officer who has filed 27 SEC Form 4 insider transactions across 4 companies since 2012. The most recent filing, for IMRX, was dated Jun 11, 2026. Across all open-market trades the lifetime net is −$3.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.92M
4
27
-$3.21M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMRX | Director | 5,500 | $4.24 | $23.3K | $19.9K | 7 | 2026-06-11 |
| ZNTL | Chief Medical Officer | 373,876 | $4.62 | $1.73M | -$42.4K | 3 | 2024-05-09 |
| ZYME | Chief Medical Officer | 7,377 | $22.61 | $166.8K | -$3.22M | 10 | 2021-03-12 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Chief Medical Officer | 5,747 | — | — | $26.7K | 5 | 2015-09-28 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-11 | IMRX | Grant (A) | — | $0 | EDGAR |
| 2025-07-07 | IMRX | Buy (P) | +5,500 | $19.9K | EDGAR |
| 2025-06-16 | IMRX | Grant (A) | — | $0 | EDGAR |
| 2024-10-31 | ZNTL | Notice (144) | −9,888 | -$28.3K | EDGAR |
| 2024-06-13 | IMRX | Grant (A) | — | $0 | EDGAR |
| 2024-05-09 | ZNTL | Notice (144) | −3,356 | -$42.4K | EDGAR |
| 2024-05-09 | ZNTL | Sell (S) | −3,356 | -$42.4K | EDGAR |
| 2024-02-05 | ZNTL | Grant (A) | +337,500 | $0 | EDGAR |
| 2023-06-15 | IMRX | Grant (A) | — | $0 | EDGAR |
| 2023-05-10 | ZNTL | Grant (A) | +39,732 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.